Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNecmettin Erbakan University

About this trial

This prospective single-center observational study aims to evaluate the relationship between elevated plasma homocysteine levels and early echocardiographic abnormalities in patients with newly diagnosed essential hypertension. Adult patients diagnosed with essential hypertension within the previous 6 months will undergo clinical assessment, ambulatory blood pressure monitoring, electrocardiography, laboratory testing, and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis when image quality is adequate. Participants will be classified according to plasma homocysteine level using, and patients with elevated and normal homocysteine levels will be compared with respect to diastolic dysfunction and left ventricular and left atrial global longitudinal strain parameters. Clinical, laboratory, and echocardiographic data will also be used to develop a machine-learning based model for prediction of H-type hypertension.

Eligibility criteria

Qualifiers

Adults aged 18 years or older

Newly diagnosed essential hypertension within the previous 6 months

Ability and willingness to provide informed consent

Availability for clinical evaluation, laboratory testing, ambulatory blood pressure monitoring, electrocardiography, and transthoracic echocardiography

Disqualifiers

Resistant hypertension

Secondary hypertension

Acute coronary syndrome within the previous 6 months

Major surgery within the previous 6 months

Trial design

Treatments tested in this trial

  • Homocysteine Measurement and Echocardiography

Treatment groups

500 Participants
are divided into 2 treatment groups

Sponsors and collaborators